source of ibogaine
Fight to develop drug addiction therapyKaren Brimingham
Nature Medicine, April 1998
A new phase in the acrimonious legal struggle over the development of the anti-addiction drug ibogaine began last month when the trial was moved to Florida. Because the trial centers on work carried out at the University of Miami, the suit was dismissed for jurisdictional reasons by courts in New York. Now the Miami judicial system is faced with resolving a case that involves the U.S. Food and Drug Administration (FDA), a senior neuroscientist, a Caribbean drug treatment center, the National Institute on Drug Abuse (NIDA) and the ibogaine use-patent holder, Howard Lotsof.
Lotsof discovered ibogaine's anti-addictive potential thirty years ago when he experimented with the drug as a 19 year old heroin addict. Since that time, he claims to have spent 17 years and $1 million trying to bring the drug to market as an addiction therapy (Endabuse) through his Staten Island company, NDA International, Inc.
Ibogaine is purported to cure heroin and cocaine addiction by removing the physiological and psychological characteristics of dependency without inducing withdrawal symptoms (Nature Med. 1;288, 1995). Remarkably, it is claimed that ibogaine achieves this effect in one dose.
Legal proceedings began last April when Deborah Mash, Professor of Neurology at the University of Miami and principal investigator in the FDA-approved Phase I trials of the drug filed a motion accusing Lotsof of fraud. Mash alleges that Lotsof covertly took out a patent on an ibogaine metabolite (Noribogaine plus) that is more effective than the parent compound - a discovery made by Mash but not attributed to her. Mash is demanding that the patent, issued to Lotsof in January 1997, be canceled and requests compensation. Her petition makes clear distinction between her reputation as a "world renowned scientist in the field of neurology" and Lotsof's lack of scientific background.
Lotsof counter-sued in August, claiming that Mash and the University of Miami violated their 1992 contract to perform the Phase I study. He further alleges that Mash is currently infringing his company's intellectual property rights for her own commercial benefit at a drug treatment facility on the Caribbean Island of St. Kitts.
Mash agrees that early clinical studies of the drug were suspended and says it was for good reason: In 1993 a woman in the Netherlands died, reportedly due to an ibogaine overdose, while being treated in a hotel room. Mash says she had an ethical responsibility to stop human testing while the affair was investigated. Furthermore, she says that NDA International was not providing financial support for the study.
Despite these problems, Mash and Lotsof were still on good terms. After the Dutch death, Mash helped Lotsof set up a program in Panama, where subjects were to be treated in medical surroundings and monitored at the University of Miami. But by the time NIDA held an ibogaine consensus meeting in 1995, their relationship had deteriorated beyond repair. The NIDA advisory panel ruled against further studies of the drug - some believe for reasons of toxicity and others say on political grounds - and the ibogaine story looked to have come to a close.
Not so, according to Mash, in 1996 a group of private individuals who had "enough respect for her as a scientist" funded a treatment center called Healing Visions in St. Kitts. Here she used ibogaine to treat private customers - one Chicago lawyer is said to have paid $12,000.00 for treatment - and all outside the reaches of US patent law.
Despite criticism that she has chosen an unconventional route to proceed with her research, Mash insists that working in St. Kitts is the only way she can collect patient data. She is dismissive of Lotsof's patent rights which she says, "won't last for ever" and plans to file for clinical trial approval in the US once she has sufficient preliminary evidence that ibogaine is safe and effective. She freely admits that she is staking her scientific career on the drug.
Lotsof is equally determined to see the project through, since he too has devoted his life to the pursuit of ibogaine as a cure for dependency. He has hired a new lawyer in Miami and is awaiting a trial start date.
© Nature Medicine, 4; 377, 1998
The Ibogaine Dossier